Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...
BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented ...
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...
2024 Weight-loss drug developer BioAge raises $198 mln in U.S. IPO September 26, 2024 Obesity drug developer BioAge Labs aims up to $640 mln valuation in upsized US IPO September 25, 2024 Obesity ...
Not only are deals going off at higher valuations than the companies initially anticipated, but the prices have been popping after the stocks began trading in the public markets. Observers are hoping ...
Morgan Stanley and Goldman Sachs issued bullish notes on BioAge (NASDAQ:BIOA) based on the company’s drug candidate azelaprag that aims to increase weight-loss while improving body composition ...
BioAge Labs is a new kid on the block. The company completed its initial public offering (IPO) on Oct. 1. The biotech's leading candidate is called azelaprag. It is being developed as a weight ...
RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback